Someone linked to this on another thread yesterday.
www.transgendertrend.com/puberty-blockers-safe/
I would want to know why a drug company, Ferring, sponsored the crucial Dutch trial into puberty blockers: the 2006 Delemarre-van de Waal and Cohen-Kettenis paper was ‘presented at the 4th Ferring Pharmaceuticals International Paediatric Endocrinology Symposium, Paris (2006)’ and Ferring Pharmaceuticals supported the publication of these proceedings.’
Ferring was interested in this novel use for their expensive drug because they market Triptorelin, one of the GnRH antagonists used in gender clinics under the brand names Diphereline and Gonapeptyl.
The Amsterdam clinic was financially supported in its experimental project to block puberty in gender dysphoric adolescents by a pharmaceutical company which stood to make commercial gains from their new protocol.
From the paper mentioned above:
Acknowledgements
The authors are very grateful to Ferring Pharmaceuticals for the financial support of studies on the treatment of adolescents with gender identity disorders